Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1328-1335

  Bakker, E M ^a   Volpi, S ^d   Salonini, E ^d   Van Der Wiel Kooij, E C ^a   Sintnicolaas, C J J C M ^c   Hop, W C J ^b   Assael, B M ^d   Merkus, P J F M ^c   Tiddens, H A W M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Cystic Fibrosis Center   (Italy)

Author keywords

Aerosol deposition; Inhaled drug delivery; Nebuliser; Paediatric; Small airways

Indexed keywords

DORNASE ALFA;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENTEROPATHY; FEMALE; FORCED EXPIRATORY FLOW; FORCED VITAL CAPACITY; HOARSENESS; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NEBULIZATION; NEBULIZER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADOLESCENT; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DOUBLE-BLIND METHOD; EXPECTORANTS; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 82555185048     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00006211     Document Type: Article

References (42)

1. Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 904-910. (Pubitemid 34774655)
2. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-1204.
3. Nixon GM, Armstrong DS, Carzino R, et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002; 87: 306-311.
4. Tiddens HA, Donaldson SH, Rosenfeld M, et al. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 2010; 45: 107-117.
5. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180: 146-152.
6. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155: 623-628.
7. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178: 1238-1244.
8. Aurora P, Bush A, Gustafsson P, et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 249-256.
9. Lethem MI, James SL, Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990; 142: 1053-1058. (Pubitemid 20384359)
10. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192. (Pubitemid 120030590)
11. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642. (Pubitemid 24276863)
12. Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Respir J 1995; 8: 1786-1791.
13. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820. (Pubitemid 34014460)
14. Gustafsson PM, De Jong PA, Tiddens HA, et al. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63: 129-134. (Pubitemid 351236476)
15. Kozlowska WJ, Bush A, Wade A, et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 42-49. (Pubitemid 351919192)
16. Hamutcu R, Rowland JM, Horn MV, et al. Clinical findings and lung pathology in children with cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 1172-1175. (Pubitemid 34415829)
17. Tiddens HA, Koopman LP, Lambert RK, et al. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. Eur Respir J 2000; 15: 735-742. (Pubitemid 30196303)
18. Brownlee KG. Small airways disease in cystic fibrosis. Eur Respir Mon 2006; 35: 21-37.
19. Diot P, Palmer LB, Smaldone A, et al. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1662-1668. (Pubitemid 27505540)
20. Laube BL, Jashnani R, Dalby RN, et al. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000; 118: 1069-1076.
21. Brand P, Meyer T, Haussermann S, et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 2005; 18: 45-54. (Pubitemid 40349946)
22. Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22: 263-267. (Pubitemid 36986995)
23. Griese M, Ramakers J, Krasselt A, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 822-828. (Pubitemid 38402458)
24. Kohler E, Sollich V, Schuster-Wonka R, et al. Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med 2005; 18: 386-395. (Pubitemid 43038405)
25. Scheuch G, Müllinger B, Brand P, et al. Optimizing aerosol lung deposition in cystic fibrosis patients. In: Romano L, Manno G, Galietta LJV, eds. Proceedings of the 25th European Cystic Fibrosis Conference. Bologna, Monduzzi Editore, 2002; pp. 169-172.
26. 1-antitrypsin deficiency. Eur Respir J 2009; 34: 354-360.
27. Devadason SG, Everard ML, Linto JM, et al. Comparison of drug delivery from conventional versus "Venturi" nebulizers. Eur Respir J 1997; 10: 2479-2483. (Pubitemid 28048619)
28. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004; 49: 174-179.
29. Newman SP, Pitcairn GR, Hooper G, et al. Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low pressure compressor system. Eur Respir J 1994; 7: 1177-1181. (Pubitemid 24187340)
30. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993; 87: 461-465. (Pubitemid 23266355)
31. Pijnenburg MW, Bakker EM, Hop WC, et al. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172: 831-836. (Pubitemid 41369065)
32. Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997; 156: 688-695. (Pubitemid 27396402)
33. van der Giessen LJ, de Jongste JC, Gosselink R, et al. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatr Pulmonol 2007; 42: 624-630. (Pubitemid 47021055)
34. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008; 177: 253-260. (Pubitemid 351198367)
35. Zapletal A, Paul T, Samanek M. Die Bedeutung heutiger Methoden der Lungenfunktionsdiagnostik zur Feststellung einer Obstruktion der Atemwege bei Kindern und Jugendlichen [Significance of contemporary methods of lung function testing for the detection of airway obstruction in children and adolescents]. Z Erkr Atmungsorgane 1977; 149: 343-371. (Pubitemid 8264588)
36. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5: 177-185. (Pubitemid 44063951)
37. Burrows JA, Bunting JP, Masel PJ, et al. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros 2002; 1: 255-259.
38. Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009; 75: 141-144.
39. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151. (Pubitemid 23187234)
40. Shah PL, Scott SF, Geddes DM, et al. An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J 1997; 10: 1261-1266. (Pubitemid 27278243)
41. Geller DE, Eigen H, Fiel SB, et al. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol 1998; 25: 83-87. (Pubitemid 28110582)
42. Geller D, Thipphawong J, Otulana B, et al. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. J Aerosol Med 2003; 16: 175-182. (Pubitemid 36702671)